Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816591 | 1.00 | L3MBTL1 (0.46) | L3MBTL1KMT2ASIGMAR1CTSKMCHR1 | |
| SCHEMBL13088860 | 1.00 | L3MBTL1 (0.46) | L3MBTL1KMT2ASIGMAR1CTSKMCHR1 | |
| SCHEMBL4373643 | 0.90 | KMT2A (0.57) | L3MBTL1KMT2ACTSKMCHR1KCNA3 | |
| SCHEMBL4373639 | 0.90 | KMT2A (0.57) | L3MBTL1KMT2ACTSKMCHR1KCNA3 | |
| SCHEMBL4373646 | 0.90 | KMT2A (0.57) | L3MBTL1KMT2ACTSKMCHR1KCNA3 | |
| SCHEMBL13434257 | 0.89 | L3MBTL1 (0.41) | L3MBTL1KMT2ASIGMAR1CTSKALDH1A1 | |
| SCHEMBL13434256 | 0.89 | L3MBTL1 (0.41) | L3MBTL1KMT2ASIGMAR1CTSKALDH1A1 | |
| SCHEMBL7794347 | 0.89 | L3MBTL1 (0.41) | L3MBTL1KMT2ASIGMAR1CTSKALDH1A1 | |
| SCHEMBL13631102 | 0.89 | L3MBTL1 (0.41) | L3MBTL1KMT2ASIGMAR1CTSKALDH1A1 | |
| SCHEMBL19876008 | 0.82 | L3MBTL1 (0.46) | L3MBTL1KMT2ASIGMAR1ALDH1A1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | L3MBTL1 3310/4885KMT2A 1812/4885SIGMAR1 354/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | L3MBTL1 3531/4885KMT2A 921/4885SIGMAR1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.